Gritstone Oncology Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gritstone Oncology in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Gritstone Oncology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRTS, but not buy additional shares or sell existing shares.
View analyst ratings for Gritstone Oncology or view top-rated stocks.

Wall Street analysts have given Gritstone Oncology a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Gritstone Oncology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Gritstone Oncology is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Gritstone Oncology.

Gritstone Oncology, Inc. (NASDAQ:GRTS) posted its earnings results on Thursday, March, 11th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by $0.08. Gritstone Oncology had a negative trailing twelve-month return on equity of 101.31% and a negative net margin of 2,962.52%.
View Gritstone Oncology's earnings history.

Gritstone Oncology's stock was trading at $6.67 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GRTS shares have increased by 29.5% and is now trading at $8.64.
View which stocks have been most impacted by COVID-19.

3 equities research analysts have issued 12-month price targets for Gritstone Oncology's shares. Their forecasts range from $8.00 to $35.00. On average, they expect Gritstone Oncology's stock price to reach $22.33 in the next year. This suggests a possible upside of 158.5% from the stock's current price.
View analysts' price targets for Gritstone Oncology or view top-rated stocks among Wall Street analysts.

1 employees have rated Gritstone Oncology CEO Andrew Allen on Glassdoor.com. Andrew Allen has an approval rating of 100% among Gritstone Oncology's employees. This puts Andrew Allen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Gritstone Oncology include Sangamo Therapeutics (SGMO), Immunovant (IMVT), REGENXBIO (RGNX), AlloVir (ALVR), Translate Bio (TBIO), Alector (ALEC), C4 Therapeutics (CCCC), Replimune Group (REPL), Forma Therapeutics (FMTX), Mesoblast (MESO), Cortexyme (CRTX), Atara Biotherapeutics (ATRA), Ocugen (OCGN), Scholar Rock (SRRK) and Coherus BioSciences (CHRS).
View all of GRTS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Gritstone Oncology investors own include ADMA Biologics (ADMA), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Novan (NOVN), Sorrento Therapeutics (SRNE), Zosano Pharma (ZSAN), Enerplus (ERF), Oncolytics Biotech (ONCY), SCYNEXIS (SCYX) and CBL & Associates Properties (CBL).

(GRTS) raised $85 million in an initial public offering on Friday, September 28th 2018. The company issued 6,100,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Barclays acted as the underwriters for the IPO and BTIG was co-manager.

Gritstone Oncology trades on the NASDAQ under the ticker symbol "GRTS."

Shares of GRTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GRTS stock can currently be purchased for approximately $8.64.

Gritstone Oncology has a market capitalization of $422.95 million and generates $4.36 million in revenue each year. The company earns $-94,430,000.00 in net income (profit) each year or ($2.81) on an earnings per share basis.

Gritstone Oncology employs 169 workers across the globe.

The official website for Gritstone Oncology is www.gritstoneoncology.com.

Gritstone Oncology is headquartered at 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608.

Gritstone Oncology's mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company can be reached via phone at 510-871-6100 or via email at [email protected]